)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Cibus
Cibus (CBUS) investor relations material
Cibus Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary13 Aug, 2026
Executive summary
CEO transition completed, with a focus on scaling revenue through proprietary, IP-protected platforms and prioritizing programs closest to commercialization, including Rice and Sustainable Ingredients.
Advanced commercialization in Rice and Sustainable Ingredients, with expanded partnerships and regulatory alignment in the US, EU, and Latin America.
Commercial progress includes converting industry conversations into ongoing partnerships, with seed companies seeking continuous trait improvements across crops.
Leadership transition completed with new CEO and continued cost reduction initiatives, targeting $35M annual net cash usage exiting 2026.
Focused on commercial ramp-up of biofragrance products and partner-funded lauric oils program in soybean.
Financial highlights
Q2 2026 revenue was $1 million, up from $0.9 million year-over-year; six-month revenue rose 36% to $2.7 million, driven by Sustainable Ingredients.
Net loss for Q2 2026 was $22.1 million, improved from $26.6 million year-over-year; net loss per share was $0.29, down from $0.61.
R&D expenses dropped to $8.5 million from $12.2 million, and SG&A to $5.4 million from $6.6 million, reflecting cost-saving initiatives.
Cash and equivalents stood at $20.4 million as of June 30, 2026; cash usage declined 19% sequentially and 31% year-over-year.
Net cash used in operating activities for H1 2026 was $20.9 million, down from $25.4 million year-over-year.
Outlook and guidance
Existing cash is expected to fund operations into early Q1 2027; annual net cash usage run-rate targeted at ~$35 million exiting 2026.
Rice royalty revenue expected to begin in 2028, ramping through 2029 as adoption expands; peak annual royalty opportunity exceeds $200 million.
Sustainable Ingredients program in commercial ramp-up, with additional scale-up orders anticipated in H2 2026.
Expects continued operating losses for several years as commercial activities scale; additional capital required to support business plans.
Board evaluating strategic alternatives to support funding needs.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cibus
- Gene editing accelerates crop innovation and royalty growth as global regulatory support expands.CBUS
LD Micro Main Event XIX Investor Conference - EU regulatory shift accelerates gene editing commercialization and royalty growth prospects.CBUSSidoti Small-Cap Virtual Investor Conference
- Directors re-elected, executive pay approved, and auditor ratified with no shareholder questions.CBUSAGM 2026
- Biotech firm targets $200M in offerings amid liquidity concerns and potential shareholder dilution.CBUSRegistration filing
- Revenue up, net loss down, and cash funds operations into late Q1 2027; more capital needed.CBUSQ1 2026
- Annual meeting covers director elections, executive pay, auditor ratification, and governance policies.CBUSProxy filing
- Key votes include director elections, executive pay approval, and auditor ratification for 2026.CBUSProxy filing
- Q3 net loss of $201.5M from goodwill impairment; cost savings and commercialization ongoing.CBUSQ3 2024
- Gene editing is transforming agriculture with rapid regulatory acceptance and high-margin royalty models.CBUSCanaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024
Next Cibus earnings date
Q3 202612 Nov, 2026
Cibus
Next Cibus earnings date
Q3 202612 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Cibus Inc., an agricultural technology company, specializes in developing and licensing plant traits to seed companies for royalties. The firm's primary focus is on trait productivity in two crucial areas: productivity traits that enhance farmers' yields while minimizing the use of crop protection chemicals and fertilizers, and sustainable ingredients that allow corporations to substitute ingredients derived from fossil fuels or those whose production contributes to increased greenhouse gases. Cibus is headquartered in San Diego, California, and its shares are listed on the Nasdaq.